A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.

Leone, Robert D; Lo, Ying-Chun; Powell, Jonathan D

Leone, Robert D; Lo, Ying-Chun; Powell, Jonathan D.

Afiliação

Leone RD; Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Lo YC; Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Powell JD; Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Comput Struct Biotechnol J ; 13: 265-72, 2015.

Article em En | MEDLINE | ID: mdl-25941561

Palavras-chave

A2a adenosine receptor; A2aR, adenosine A2a receptor; APC, antigen presenting cell; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DLBCL, diffuse large B-cell lymphoma; Hif1-alpha, hypoxia inducible factor-1 alpha; Immune checkpoint; Immunotherapy; LAG-3, lymphocyte-activation gene 3; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PD-1; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1; T cell; TFS, tumor free survival; TIM-3, T-cell immunoglobulin domain and mucin domain 3; Treg, regulatory T cell; Tumor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article